Efficacy and safety of darusentan: A novel endothelin receptor antagonist

Annals of Pharmacotherapy

Volumn 42, Issue 7-8, 2008, Pages 1060-1069

  Epstein, Benjamin J ^a,b,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b East Coast Institute for Research   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cardiovascular disease; Darusentan; Endothelin receptor antagonist; Heart failure; Hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EMBASE; ERYTHROCYTE COUNT; FLUSHING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HEART FAILURE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; LIVER TOXICITY; MEDLINE; OUTCOMES RESEARCH; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; HEART FAILURE; HUMANS; HYPERTENSION; PHENYLPROPIONATES; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; SUBSTRATE SPECIFICITY;

EID: 48249109076     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L024     Document Type: Review

References (54)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.
2. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360: 1903-13.
3. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-76.
4. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106:3068-72.
5. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on BP control: main results of the PREMIER clinical trial. JAMA 2003;289:2083-93.
6. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and BP reduction: a meta-analysis. Lancet 2001;358:1305-15.
7. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007;297:61-70.
8. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992;85:510-7.
9. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in congestive heart failure. Circulation 1992;85:1374-9.
10. Larivière R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993;21:294-300.
11. Touyz RM, Schiffrin EL. Role of endothelin in human hypertension. Can J Physiol Pharmacol 2003;81:533-41.
12. Ergul S, Parish DC, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996;28:652-5.
13. Ergul S, Ergul A, Hudson JA, et al. The effect of regulation of high BP on plasma ET-1 levels in blacks with hypertension. Am J Hypertens 1998;11:1381-5.
14. Ergul A. Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension 2000;36:62-7.
15. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 2005;43:19-29.
16. Shreenivas S, Oparil S. The role of endothelin-1 in human hypertension. Clin Hemorheol Microcirc 2007;37:157-78.
17. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
18. Kaplan NM. Resistant hypertension. J Hypertens 2005;23:1441-4.
19. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med 2006;355:385-92.
20. Battistini B, Berthiaume N, Kelland NF, et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class. Exp Biol Med (Maywood) 2006;231:653-95.
21. Abassi ZA, Ellahham S, Winaver J, Hofman A. The intrarenal endothelin system and hypertension. News Physiol Sci 2001;16:52-6.
22. Douglas SA, Nambi P, Gellai M, et al. Pharmacologic characterization of the novel, orally available endothelin-A-selective antagonist SB 247083. J Cardiovasc Pharmacol 1998;31(suppl 1):S273-6.
23. Givertz MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000;101:2922-7.
24. Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 2006;110:386-414.
25. B receptor selectivity of endothelin-1 receptor antagonists in human myocardial membranes (abstract). J Am Coll Cardiol 2006;47:307A.
26. A-selective endothelin receptor antagonism on BP in experimental and genetic hypertension in rats. Br J Pharmacol 1997;121:935-40.
27. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Lüscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997;96:1593-7.
28. d'Uscio LV, Barton M, Shaw S, Moreau P, Lüscher TF. Structure and function of small arteries in salt-induced hypertension: effects of chronic endothelin-subtype-A-receptor blockade. Hypertension 1997;30:905-11.
29. A receptor blockade attenuates cardiac hypertrophy independently of BP effects in renovascular hypertensive rats. Hypertension 1999;33:954-60.
30. Orth SR, Esslinger JP, Amann K, Schwarz U, Raschack M, Ritz E. Nephroprotection of an ET(A)-receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. Hypertension 1998;31:995-1001.
31. Hocher B, Schwarz A, Reinbacher D, et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001;87:161-9.
32. Gourine AV, Gonon AT, Pernow J. Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2001;280:H1105-12.
33. Nakov R, Pfarr E, Eberle S, et al. Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 2002; 15:583-9.
34. Raschack M, Unger L, Riechers H, Klinge D. Receptor selectivity of endothelin antagonists and prevention of vasoconstriction and endothelin-induced sudden death. J Cardiovasc Pharmacol 1995;26(suppl 3):S397-9.
35. Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev 2006;24:63-76.
36. Cernacek P, Franchi L, Dupuis J, Rouleau JL, Levy M. Radioreceptor assay of an endothelin A receptor antagonist in plasma and urine. Clin Chem 1998;44:1666-73.
37. Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens 2007;9:760-9.
38. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839-45. Epub 19 Feb 2007.
39. Carl D, Sica DA. Spironolactone use in resistant hypertension. Curr Hypertens Rep 2007;9:297-8.
40. ClinicalTrials.gov. http://clinicaltrials.gov (accessed 2008 May 20).
41. Bergler-Klein J, Pacher R, Berger R, Bojic A, Stanek B. Neurohumoral and hemodynamic effects of the selective endothelin antagonist darusentan in advanced chronic heart failure. J Heart Lung Transplant 2004;23:20-7.
42. Luscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002;106:2666-72.
43. Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the endothelin A receptor antagonist trial in heart failure (EARTH): randomized, double-blind, placebo-controlled trial. Lancet 2004;364:347-54.
44. Ertl G, Bauersachs J. Endothelin receptor antagonists in heart failure: current status and future directions. Drugs 2004;64:1029-40.
45. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol 2008; 101:223-30.
46. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
47. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223-31.
48. Opitz CF, Ewert R. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension. Eur J Clin Invest 2006;36(suppl 3):1-9.
49. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;368:703-10.
50. Kurihara Y, Kurihara H, Oda H, et al. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest 1995;96:293-300.
51. Kurihara Y, Kurihara H, Maemura K, Kuwaki T, Kumada M, Yazaki Y. Impaired development of the thyroid and thymus in endothelin-1 knockout mice. J Cardiovasc Pharmacol 1995;26:13-6.
52. Elijovich F, Laffer CL, Gavras H, Bresnahan MR, Schiffrin EL. Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation 2001;103:263-8.
53. Ferri C, Bellini C, Desideri G. Elevated plasma and urinary endothelin-1 levels in human salt-sensitive hypertension. Clin Sci 1997;93:35-41.
54. Ferri C, Bellini C, Desideri G, et al. Clustering of endothelial markers of vascular damage in human salt-sensitive hypertension: influence of dietary sodium load and depletion. Hypertension 1998;32:862-8.